Syncona (LSE:SYNC), the London-listed life sciences investor, grew its portfolio value to £839.4 million in the year ended 31 March, up from £765.4 million a year earlier, generating a return of 1.7% on the life science portfolio.
The gain was driven principally by a write-up of Beacon Therapeutics following its $75 million Series C financing round, led by Goldman Sachs Alternatives and described as oversubscribed, in which Syncona committed $24.5 million alongside new and existing investors.
The capital pool contracted to £198.3 million at period end from £287.7 million, with £80.9 million deployed during the year, weighted 83.7% toward clinical or late-stage clinical assets.
Offsetting the Beacon uplift, portfolio company Kesmalea was written down amid what Syncona described as "challenging private biotech market conditions for early-stage companies", following advanced interest from potential third-party investors.
The company flagged four key value inflection points expected before the end of calendar 2026, including a Phase III pivotal trial data readout from Beacon in X-linked retinitis pigmentosa (XLRP) and Phase IIb data from iOnctura in metastatic uveal melanoma.
Syncona said it is "cautiously optimistic" that recovering biotech public markets will translate into improved private financing conditions, with significant pharma M&A activity in 2025 continuing into 2026 providing a supportive backdrop for its maturing portfolio of 15 companies.
